Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
56
resultados
Última actualización
27/04/2026 [08:29:00]
Resultados 25 a 50 de 56
Resumen de: AU2024353668A1
Described herein are Casitas B-lineage lymphoma (Cbl) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or condition associated with Cbl-b activity, such as cancers.
Resumen de: AU2024366453A1
The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.
Resumen de: AU2024352563A1
The invention relates to the field of leukemia/lymphoma diagnosis, more specifically to the detection of MRD in bone marrow, blood and other fluids and tissues from patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/T-LBL). Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in T-ALL and/or T-LBL, the reagent composition comprising a panel of at least four antibodies conjugated to a detectable label, the panel comprising antibodies against markers NKp80, CD16, cyCD3 and smCD3.
Resumen de: AU2024369003A1
The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).
Resumen de: AU2024380949A1
The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.
Resumen de: US20260103515A1
The present disclosure relates to doses and dosing regimens of a bispecific antibody that binds myeloid cell surface antigen CD33, and the Vδ2 chain of the human Vγ9Vδ2 T cell receptor; to pharmaceutical compositions comprising said antibodies, as well as methods of administration of the referred doses, and to the use of said antibodies in the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Neoplasms (MDS), in particular Relapsed or Refractory (R/R) AML or MDS.
Resumen de: US20260102397A1
The present invention relates to a pharmaceutical composition for the treatment of leukemia comprising an FMS-like tyrosine kinase-3 (FLT3) inhibitor and a pharmaceutically acceptable excipient.
Resumen de: WO2026078067A1
The present disclosure relates to human/cynomolgus cross-reactive antibody arms that bind specifically to FcRH5, which preferentially bind to membrane-bound FcRH5 (isoform c) and which do not cross-react with other FcRH family members. The present disclosure relates to bispecific antibodies which bind to human FcRH5 using the anti-FcRH5 arms described herein and bind to human CD28. The bispecific antibodies of the disclosure provide FcRH5-dependent costimulatory signal to T cells, even in the presence of soluble FcRH5, enhancing T cell mediated anti-tumor immunity against FcRH5-expressing cancers such as multiple myeloma.
Resumen de: WO2026078200A1
This invention relates to recombinant mammalian cells and their use in treating cancer. The present invention specifically relates to the co-expression of an adapter CAR and a conventional CAR in CAR T cells and the use of these cells in treating lymphoma. The invention also relates to pharmaceutical compositions comprising such recombinant mammalian cells, as well as their uses in cancer therapy.
Resumen de: US20260102490A1
Embodiments disclosed herein relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of BCMA×GPRC5D×CD3 trispecific antibody or trispecific binding fragment thereof and an anti-CD38 antibody, to the subject to the subject to treat the multiple myeloma.
Resumen de: WO2026078647A1
Embodiments described herein relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, and pomalidomide, to the subject to treat the multiple myeloma.
Resumen de: WO2026077416A1
A method for treating peripheral T cell lymphoma. Specifically, the present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in combination with the CHOP combination or CHOEP combination in the preparation of a drug for treating mature lymphocytic tumors.
Resumen de: US20260104330A1
The present invention discloses a leukemia cell separation and extraction device, comprising a sampling tube and a filtration assembly. Top end of inner wall of sampling tube is equipped with multiple limit blocks, while filtration assembly includes a retaining ring installed at top opening of the sampling tube, with one side contacting the limit blocks. The bottom end of inner wall of retaining ring is connected to an air duct via multiple connecting plates, with membranes between each plate. Main drainage rods, inclined and circumferentially arranged, connect the air duct's outer wall to the retaining ring's inner wall, with zigzag secondary drainage rods between them. One end of the retaining ring is attached to a push plate, and a collecting assembly is mounted on the air duct. This configuration allows for efficient plasma extraction from blood samples, retaining blood cells in the original container and enhancing separation efficiency.
Resumen de: WO2026078266A1
The present invention refers to anti-BCMA specific single domain antibodies, and their use in chimeric antigen receptor cells, specifically T cells, which are of use in the treatment of cancer characterized by an increase in cells expressing BCMA, in particular multiple myeloma.
Resumen de: WO2024254455A1
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
Resumen de: GB2644560A
Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
Resumen de: EP4726031A1
This disclosure discloses a CLL1-CAR-T cell, as well as their preparation methods and applications. Specifically, it reveals CLL1-CAR-T cell that contain a chimeric antigen receptor, which comprises a single-domain antibody, a hinge region, a transmembrane region, and an intracellular signaling region. The amino acid sequence of the single-domain antibody corresponds to positions 22-150 of SEQ ID No.1. The CLL1-VHH-1 CAR-T cells of this disclosure can effectively secrete the T-cell-specific effector molecule IFN-γ, specifically and efficiently kill CLL1+ target cells, and exhibit favorable in vivo anti-tumor activity. They not only significantly inhibit the proliferation of tumor cells in mice but also markedly prolong the survival time of mice. The CLL1-VHH-1 CAR-T cells of this disclosure demonstrate excellent anti-tumor capabilities and can be used for immunotherapy of diseases related to the CLL1 target, such as acute myeloid leukemia, presenting broad prospects for clinical applications.
Resumen de: WO2026074086A1
The present invention relates to cells expressing chimeric antigen receptors against BCMA and a glutamine transporter, and uses thereof in the treatment of cancer or autoimmune diseases. The invention also relates to a method for the prognosis of multiple myeloma in a subject.
Resumen de: WO2026076363A1
Provided herein is the use of particular dose levels or amounts of certain pyruvate kinase activators or pharmaceutically acceptable salts or compositions thereof, for treating anemia associated with low risk MDS, lower risk MDS and/or intermediate risk MDS (collectively, LRMDS) and other conditions.
Resumen de: AU2025316407A1
The present disclosure is directed to methods of treating, for example, newly diagnosed multiple myeloma.
Resumen de: AU2024339935A1
The invention relates to a modified immune cells for use in the treatment of a solid tumor in a subject, wherein the modified immune cell comprises one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancerous cell of said solid tumor, in said immune cell, Nuclear Receptor Subfamily 2 Group F Member 6 (NR2F6) activity is inhibited (in comparison to a control immune cell), and binding of the immune cell to the antigen is associated with death of said cancerous cell expressing the antigen, and inducing a secondary immune reaction in the subject against cancerous cells of the solid tumor, wherein said secondary immune reaction is non-specific to the antigen targeted by the transgenic construct (epitope spreading). The invention relates further to a modified immune cell comprising one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancerous cell of a solid tumor, wherein in said cell, NR2F6 activity and Casitas B-lineage lymphoma proto-oncogene-b (CBLB) activity is inhibited (compared to a control immune cell). The invention relates further to a pharmaceutical composition comprising the modified immune, suitable for the treatment of a solid tumor, comprising additionally a pharmaceutically acceptable carrier, and to an in vitro method for enhancing the cytolytic activity of a modified immune cell.
Resumen de: US20260098097A1
0000 Methods of treating various types of cancer, including cutaneous T-cell lymphoma, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin, alone, or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an antibody-drug conjugate.
Resumen de: US20260097122A1
The present disclosure relates to CD19/22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.
Resumen de: AU2026202107A1
The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens. 5 ar a r
Nº publicación: WO2026076264A1 09/04/2026
Solicitante:
TREELINE BIOSCIENCES INC [US]
Resumen de: WO2026076264A1
Provided here are methods of treating lymphomas for example, peripheral T-cell lymphomas (PTCLs) (e.g., nodal Tfh cell lymphomas) and/or cutaneous T-cell lymphomas (CTCLs) in a subject, by administering to the subject Compound A, or a pharmaceutically acceptable salt thereof. In some cases, the lymphomas are BCL6 positive. In some cases, the lymphomas are relapsed or refractory. In some cases, the subjects are treatment-naïve (i.e., previously untreated).
BOPI
Sede Electrónica
